VMQ StocksFor the value investor looking to harness academic research in
an actively managed portfolio
Bits and BipsNewsletter delivering insights on linking traditional finance, macro trends and cryptocurrency opportunities to help investors build stronger, more diversified portfolios.
All premium products come with free basic membership.
IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer’s disease in the United States and Colombia. The company’s lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer’s. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer’s disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare providers. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc. was incorporated in 2005 and is headquartered in Potomac, Maryland.
Learn more about India Globalization Capital, Inc.'s (IGC) stock grades for Value, Momentum and Growth and determine whether this Business Support Services stock meets your investment needs.
Jack Gilleland
Financial Summary
Share Statistics
IGC
Industry Median
Percentile (All Stocks)
Market Cap (Mil)
$25.0
$569.9
12%
Shares Out (Mil)
98.2
44.8
62%
Institutional Ownership
57.3%
84.6%
38%
Float (Mil)
86.1
45.1
58%
Beta
0.45
0.67
25%
Avg Daily Volume (000s)
323
294
52%
Price Change (52-week)
(32.6%)
65.2%
23%
Growth
IGC
Industry Median
Percentile (All Stocks)
Sales (5yr)
(20.5%)
6.7%
2%
Net Income (5yr)
0.6%
(2.0%)
40%
EPS (5yr)
12.9%
14.9%
52
Dividends (5yr)
0.0%
0.0%
0%
Cash Flow (5yr)
53.5%
(14.9%)
94%
Estimates
Qtrly
Current Fiscal Year
Next Fiscal Year
# of Estimates
2
1
na
Current EPS
($0.020)
($0.090)
na
Month Ago EPS
($0.020)
($0.090)
na
# Rev Up
na
0
na
# Rev Down
na
1
na
Three Months Ago EPS
($0.020)
($0.090)
na
Year/Year Chg
(16.7%)
(3.2%)
(8.6%)
Financials
IGC
Industry Median
Percentile (All Stocks)
Sales (TTM) (Mil)
$1
$230
2%
Net Income (TTM) (Mil)
($6)
($11)
32%
EPS (TTM)
($0.078)
($0.600)
37%
Operating Cash Flow (TTM) (Mil)
($6)
($6)
24%
Net Cash Flow (TTM) (Mil)
$-0
$4
43%
Long-Term Debt (Q1) (Mil)
$0
$7
12%
Enterprise Value (Q1) (Mil)
$27
$493
12%
Valuation
IGC
Industry Median
Percentile (All Stocks)
P/B
4.16
2.89
74%
P/E
na
20.6
na
Dividend Yield
0.0%
0.0%
0%
PEG (5yr hist)
na
1.1
na
Ratios
IGC
Industry Median
Percentile (All Stocks)
Gross Margin
46.2%
65.9%
58%
Net Margin
(582.8%)
(0.2%)
1%
ROA
(71.9%)
(25.5%)
8%
ROE
(103.5%)
(21.4%)
9%
Liabilities to Assets
33.4%
35.5%
24%
F-Score
2
3
7%
IGC Pharma, Inc. did not pass any screens on 7/30/2026.
Looking for access to this powerful feature? Take the first step in becoming an A+ Investor today.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors